Moderate

Tricuspid regurgitation — chronic management

Right-sided valve disease · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Tricuspid regurgitation is most often secondary (functional) from annular dilatation and right-ventricular remodelling, frequently linked to left-heart disease, atrial fibrillation or pulmonary hypertension. Severe disease causes right heart failure and benefits from earlier recognition and intervention.

Red flags

  • Refractory ascites and peripheral oedema
  • Progressive right heart failure
  • Cardiac cachexia
  • Worsening hepatic/renal function from congestion
  • Severe TR with declining RV function

Assessment

Differential diagnosis

  • Secondary (functional) TR
  • Primary TR (endocarditis, rheumatic, carcinoid, device-lead)
  • Right heart failure of other cause
  • Constrictive pericarditis
  • Ebstein anomaly
  • Hepatic congestion of non-cardiac origin

Investigations

  • Transthoracic echo (TR severity, annular size, RV function)
  • Transoesophageal echo for valve morphology and intervention planning
  • ECG (atrial fibrillation, RV strain)
  • Right-heart catheterisation for pulmonary pressures
  • Liver function and congestion markers
  • Cardiac CT/MRI for RV volumes and procedural planning

Management

  • Grade severity and determine whether primary or secondary
  • Identify and treat drivers: left-heart disease, pulmonary hypertension, atrial fibrillation
  • Optimise diuretic therapy for congestion
  • Treat atrial fibrillation (rhythm/rate control) which worsens functional TR
  • Address left-sided valve lesions — improving them often improves TR
  • Refer severe primary TR for surgical repair/replacement before RV failure develops
  • Consider concomitant tricuspid repair during left-sided valve surgery when the annulus is dilated
  • Assess transcatheter tricuspid intervention for high-surgical-risk symptomatic severe secondary TR
  • Monitor RV function and avoid operating too late
  • Manage hepatic and renal consequences of chronic congestion
  • Provide anticoagulation if atrial fibrillation present
  • Arrange structured valve-clinic follow-up

Drugs & doses

Furosemide 40-120 mg PO OD (or bumetanide 1-5 mg OD) for congestion
Spironolactone 25-50 mg PO OD (aldosterone antagonism, congestion)
Apixaban 5 mg PO BD if atrial fibrillation present
Treat underlying left-heart failure with guideline-directed therapy

Disposition

Refer to a heart-valve multidisciplinary team; surgical or transcatheter intervention for severe symptomatic disease. Valve-clinic surveillance otherwise.

Complications & pitfalls

  • Right ventricular failure
  • Hepatic congestion and cardiac cirrhosis
  • Renal dysfunction (cardiorenal)
  • Atrial arrhythmias
  • Poor surgical outcomes if intervention delayed

Exam pearls

  • Isolated late tricuspid surgery after prior left-heart surgery carries high risk — address TR earlier
  • Treating atrial fibrillation and left-heart disease often improves functional TR
  • Transcatheter tricuspid therapies are expanding options for high-risk patients
  • Severe TR is frequently under-recognised and under-treated
  • Right ventricular failure, once advanced, limits reversibility

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.